459 related articles for article (PubMed ID: 17456656)
1. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
Gan TJ; Apfel CC; Kovac A; Philip BK; Singla N; Minkowitz H; Habib AS; Knighton J; Carides AD; Zhang H; Horgan KJ; Evans JK; Lawson FC;
Anesth Analg; 2007 May; 104(5):1082-9, tables of contents. PubMed ID: 17456656
[TBL] [Abstract][Full Text] [Related]
2. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
3. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
5. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant.
Diemunsch P; Apfel C; Gan TJ; Candiotti K; Philip BK; Chelly J; Carides AD; Evans JK; Ho TW; Reiss T
Curr Med Res Opin; 2007 Oct; 23(10):2559-65. PubMed ID: 17845742
[TBL] [Abstract][Full Text] [Related]
6. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
7. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
10. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery.
Diemunsch P; Gan TJ; Philip BK; Girao MJ; Eberhart L; Irwin MG; Pueyo J; Chelly JE; Carides AD; Reiss T; Evans JK; Lawson FC;
Br J Anaesth; 2007 Aug; 99(2):202-11. PubMed ID: 17540667
[TBL] [Abstract][Full Text] [Related]
11. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
12. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting.
Gan TJ; Sinha AC; Kovac AL; Jones RK; Cohen SA; Battikha JP; Deutsch JS; Pergolizzi JV; ; Glass PS
Anesth Analg; 2009 May; 108(5):1498-504. PubMed ID: 19372328
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Gore L; Chawla S; Petrilli A; Hemenway M; Schissel D; Chua V; Carides AD; Taylor A; Devandry S; Valentine J; Evans JK; Oxenius B;
Pediatr Blood Cancer; 2009 Feb; 52(2):242-7. PubMed ID: 18985740
[TBL] [Abstract][Full Text] [Related]
15. Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study.
Argiriadou H; Papaziogas B; Pavlidis T; Parlapani A; Georgiou M; Papagiannopoulou P; Papaziogas T
Surg Endosc; 2002 Jul; 16(7):1087-90. PubMed ID: 12165828
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy.
Habib AS; Keifer JC; Borel CO; White WD; Gan TJ
Anesth Analg; 2011 Apr; 112(4):813-8. PubMed ID: 21081776
[TBL] [Abstract][Full Text] [Related]
17. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
McCrea JB; Majumdar AK; Goldberg MR; Iwamoto M; Gargano C; Panebianco DL; Hesney M; Lines CR; Petty KJ; Deutsch PJ; Murphy MG; Gottesdiener KM; Goldwater DR; Blum RA
Clin Pharmacol Ther; 2003 Jul; 74(1):17-24. PubMed ID: 12844131
[TBL] [Abstract][Full Text] [Related]
18. The use of oral granisetron versus intravenous ondansetron for antiemetic prophylaxis in patients undergoing laparoscopic surgery: the effect on emetic symptoms and quality of recovery.
White PF; Tang J; Hamza MA; Ogunnaike B; Lo M; Wender RH; Naruse R; Sloninsky A; Kariger R; Cunneen S; Khalili T
Anesth Analg; 2006 May; 102(5):1387-93. PubMed ID: 16632815
[TBL] [Abstract][Full Text] [Related]
19. Ondansetron and dexamethasone dose combinations for prophylaxis against postoperative nausea and vomiting.
Paech MJ; Rucklidge MW; Lain J; Dodd PH; Bennett EJ; Doherty DA
Anesth Analg; 2007 Apr; 104(4):808-14. PubMed ID: 17377086
[TBL] [Abstract][Full Text] [Related]
20. Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery.
Aouad MT; Siddik-Sayyid SM; Taha SK; Azar MS; Nasr VG; Hakki MA; Zoorob DG; Baraka AS
Eur J Anaesthesiol; 2007 Feb; 24(2):171-8. PubMed ID: 16938159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
